Shelton Capital Management trimmed its position in DaVita Inc. (NYSE:DVA - Free Report) by 19.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,818 shares of the company's stock after selling 14,900 shares during the period. Shelton Capital Management owned approximately 0.08% of DaVita worth $9,245,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Invesco Ltd. lifted its stake in DaVita by 20.9% during the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after purchasing an additional 275,284 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after buying an additional 92,014 shares in the last quarter. Amundi lifted its position in shares of DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after acquiring an additional 240,126 shares during the last quarter. KBC Group NV grew its holdings in shares of DaVita by 0.8% in the 4th quarter. KBC Group NV now owns 316,155 shares of the company's stock worth $47,281,000 after acquiring an additional 2,636 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in shares of DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock worth $39,712,000 after purchasing an additional 12,339 shares during the period. 90.12% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the company. Barclays increased their price target on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Thursday. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $166.33.
Get Our Latest Analysis on DaVita
DaVita Stock Up 1.4 %
DaVita stock traded up $2.12 during trading hours on Friday, hitting $155.48. The company had a trading volume of 581,032 shares, compared to its average volume of 823,503. The firm's fifty day moving average is $152.13 and its 200-day moving average is $156.59. The firm has a market capitalization of $12.44 billion, a P/E ratio of 14.48, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21.
DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
